Blocking and reversing liver fibrosis with traditional Chinese medicine compound prescriptions: Beyond the known frontiers

Zhaofang BAI; Xiaoyan ZHAN; Guiji LYU; Yongping YANG

doi:10.3969/j.issn.1001-5256.2023.02.004

Volume 39 Issue 2

Feb. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(2): 273-277

PDF( 1874 KB)

Blocking and reversing liver fibrosis with traditional Chinese medicine compound prescriptions: Beyond the known frontiers

DOI: 10.3969/j.issn.1001-5256.2023.02.004

Zhaofang BAI^{1, 2},
Xiaoyan ZHAN^{1, 2},
Guiji LYU^{1, 2},
Yongping YANG^{1
,
,
,}

1.
Department of Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
2.
China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

Research funding:

National Science and Technology Key Project (2018ZX10725506);

National Science and Technology Major Project "Key New Drug Creation and Manufacturing Program" (2017ZX09301022)

More Information

Corresponding author: YANG Yongping, yongpingyang@hotmail.com (ORCID: 0000-0002-8307-1095)
Received Date: 2022-12-10
Accepted Date: 2023-01-12
Published Date: 2023-02-20

Abstract

Abstract

Liver fibrosis is the inevitable course for the progression of chronic hepatitis B to liver cirrhosis and is also the most important risk factor for hepatocarcinogenesis, and therefore, blocking and reversing liver fibrosis is an important strategy to effectively reduce the development of chronic hepatitis B cirrhosis and liver cancer. There are currently no effective drugs and measures for the treatment of liver fibrosis in Western medicine, and traditional Chinese medicine (TCM) has unique advantages in the treatment of liver fibrosis; however, due to a lack of strict and standardized clinical research, there is still no high-quality evidence for support from the aspect of evidence-based medicine (EBM). With subsidies from National Science and Technology Major Project in the 12th and 13th five-year plans, the authors conducted a multicenter, randomized, double-blind, placebo-controlled clinical trial on compound Biejia Ruangan tablets combined with entecavir in blocking and reversing chronic hepatitis B liver fibrosis. With liver biopsy as the gold standard, 1000 patients were enrolled to confirm the efficacy of compound Biejia Ruangan tablets combined with entecavir in blocking and reversing liver fibrosis and cirrhosis, and this study has become the first clinical trial investigating the anti-liver fibrosis effect of TCM supported by high-quality EBM evidence, bringing great hope to patients with chronic liver diseases and helping TCM move towards the world. This article introduces these research findings and reviews the current status and challenges of TCM in blocking and reversing liver fibrosis.
- Hepatitis B, Chronic,
- Liver Fibrosis,
- Drugs, Chinese Herbal,
- Biejia-Ruangan compound

FullText(HTML)

References(20)

References

[1]	YIN C, EVASON KJ, ASAHINA K, et al. Hepatic stellate cells in liver development, regeneration, and cancer[J]. J Clin Invest, 2013, 123(5): 1902-1910. DOI: 10.1172/JCI66369.
[2]	FRIEDMAN SL. Liver fibrosis - from bench to bedside[J]. J Hepatol, 2003, 38 Suppl 1: S38-S53. DOI: 10.1016/s0168-8278(02)00429-4.
[3]	Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice (2019)[J]. J Clin Hepatol, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007. 中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
[4]	RONG G, CHEN Y, YU Z, et al. Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: A multicenter, randomized, double-blind, placebo-controlled trial[J]. J Infect Dis, 2022, 225(6): 1091-1099. DOI: 10.1093/infdis/jiaa266.
[5]	JI D, CHEN Y, BI J, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B[J]. J Hepatol, 2022, 77(6): 1515-1524. DOI: 10.1016/j.jhep.2022.07.018.
[6]	WU YY. Effect of compound Biejia Ruangan Tablet on HBV DNA replication and hepatic fibrosis in patients with hepatitis B cirrhosis[J]. J North Pharm, 2018, 15(3): 22-23. DOI: 10.3969/j.issn.1672-8351.2018.03.013. 吴玉叶. 复方鳖甲软肝片对乙肝肝硬化患者HBV-DNA复制及肝纤维化的影响[J]. 北方药学, 2018, 15(3): 22-23. DOI: 10.3969/j.issn.1672-8351.2018.03.013.
[7]	ZHANG L, SCHUPPAN D. Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype[J]. J Hepatol, 2014, 61(1): 166-168. DOI: 10.1016/j.jhep.2014.03.009.
[8]	CHEN WJ, MAO X, GUO XD, et al. Investigation on anti-liver cancer potential and compatibility characteristics of Fufang Biejia Ruangan Pian from network perspective[J]. Chin J Exp Med Formul, 2020, 26(24): 11-22. DOI: 10.13422/j.cnki.syfjx.20202352. 陈文佳, 毛霞, 郭晓东, 等. 从网络视角探讨复方鳖甲软肝片的抗肝癌潜能及其组方功效配伍特点[J]. 中国实验方剂学杂志, 2020, 26(24): 11-22. DOI: 10.13422/j.cnki.syfjx.20202352.
[9]	SU ZB. Effect analysis of Compound Biejia Ruangan Tablet and Entecavir on Cirrhosis after hepatitis B[J]. Clin Res, 2018, 26(2): 170-172. DOI: 10.3969/j.issn.1004-8650.2018.02.094. 苏志波. 复方鳖甲软肝片与恩替卡韦治疗乙肝后肝硬化的效果分析[J]. 临床研究, 2018, 26(2): 170-172. DOI: 10.3969/j.issn.1004-8650.2018.02.094.
[10]	ZHOU J, CHEN XM, LIU SW, et al. Effects of Biejia Ruangan Tablet-containing serum on matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in cultured renal interstitial fibroblasts[J]. Chin J Integr Med, 2015, 21(2): 152-156. DOI: 10.1007/s11655-014-1784-0.
[11]	YANG FR, FANG BW, LOU JS. Effects of Fufang Biejia Ruangan pills on hepatic fibrosis in vivo and in vitro[J]. World J Gastroenterol, 2013, 19(32): 5326-5333. DOI: 10.3748/wjg.v19.i32.5326.
[12]	GUO SG, ZHANG W, JIANG T, et al. Influence of serum collected from rat perfused with compound Biejiaruangan drug on hepatic stellate cells[J]. World J Gastroenterol, 2004, 10(10): 1487-1494. DOI: 10.3748/wjg.v10.i10.1487.
[13]	ZHAO ZJ, ZHANG XX, YANG MJ, et al. Effects of Fufangbiejiaruangan Tablets on expression of TGF-β1 and mRNA in rat renal cortex after unilateral ureteral obstraction[J]. J Beijing Univ Chin Med, 2005, 28(2): 23-25. DOI: 10.3321/j.issn:1006-2157.2005.02.010. 赵宗江, 张新雪, 杨美娟, 等. 复方鳖甲软肝片对输尿管结扎大鼠肾组织TGF-β1蛋白及其mRNA表达的影响[J]. 北京中医药大学学报, 2005, 28(2): 23-25. DOI: 10.3321/j.issn:1006-2157.2005.02.010.
[14]	ZHANG DW, WANG JF, NIU JZ, et al. Influence of compound biejia ruangan prescription on extracelluar matrix in bleomycin induced pulmonary fibrosis rats[J]. China J Chin Mater Med, 2004, 29(1): 62-66. DOI: 10.3321/j.issn:1001-5302.2004.01.019. 张东伟, 王继峰, 牛建昭, 等. 复方鳖甲软肝方对肺纤维化大鼠细胞外基质的影响[J]. 中国中药杂志, 2004, 29(1): 62-66. DOI: 10.3321/j.issn:1001-5302.2004.01.019.
[15]	ZHAO JM, ZHOU GD, LI WS, et al. An experimental study on the mechanism of anti-hepatic fibrosis with Chinese medicinal herbs Fufangbiejiaruanganpian[J]. Med J Chin PLA, 2004, 29(7): 560-562. DOI: 10.3321/j.issn:0577-7402.2004.07.002. 赵景民, 周光德, 李文淑, 等. 复方鳖甲软肝片抗肝纤维化机制的实验研究[J]. 解放军医学杂志, 2004, 29(7): 560-562. DOI: 10.3321/j.issn:0577-7402.2004.07.002.
[16]	ZHAO ZM, ZHU CW, HUANG JQ, et al. Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: A single arm clinical objective performance criteria trial[J]. J Ethnopharmacol, 2022, 298: 115599. DOI: 10.1016/j.jep.2022.115599.
[17]	HASSANEIN T, TAI D, LIU C, et al. Efficacy and safety of a botanical formula fuzheng huayu for hepatic fibrosis in patients with CHC: Results of a phase 2 clinical trial[J]. Evid Based Complement Alternat Med, 2022, 2022: 4494099. DOI: 10.1155/2022/4494099.
[18]	SHI K, LIU Y, WANG X, et al. Adjuvant fuzheng huayu capsule reduces the incidence of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis[J]. Evid Based Complement Alternat Med, 2020, 2020: 8826091. DOI: 10.1155/2020/8826091.
[19]	MIAO L, YANG WN, DONG XQ, et al. Combined anluohuaxianwan and entecavir treatment significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection[J]. Chin J Hepatol, 2019, 27(7): 521-526. DOI: 10.3760/cma.j.issn.1007-3418.2019.07.009. 苗亮, 杨婉娜, 董晓琴, 等. 安络化纤丸联合恩替卡韦治疗可显著提高慢性乙型肝炎病毒感染者肝纤维化的改善率[J]. 中华肝脏病杂志, 2019, 27(7): 521-526. DOI: 10.3760/cma.j.issn.1007-3418.2019.07.009.
[20]	WANG GQ. The latest research progress of Anluo Chemical Fiber in reversing liver fibrosis/cirrhosis during the 13th Five-Year Plan[R]. Beijing: The 15th Beijing Forum on Infectious Diseases and Liver Diseases, 2022. 王贵强. 安络化纤逆转肝纤维化/肝硬化十三五重大专项最新研究进展[R]. 北京: 第十五届北京感染病和肝病论坛, 2022.

Relative Articles

[1]	Changxu LI, Xuemin LI, Zhanqiang LIANG, Xibin DUAN, Pengsheng YANG. Application of indocyanine green fluorescence navigation in laparoscopic cholecystectomy after percutaneous transhepatic gallbladder drainage in elderly patients with acute cholecystitis[J]. Journal of Clinical Hepatology, 2023, 39(4): 885-891. doi: 10.3969/j.issn.1001-5256.2023.04.020
[2]	Xuelian PENG, Xiaoqing XU, Qin CAO. Clinical efficacy and safety of Danshu Capsule in treatment of chronic cholecystitis and gallstones[J]. Journal of Clinical Hepatology, 2022, 38(9): 2084-2090. doi: 10.3969/j.issn.1001-5256.2022.09.025
[3]	Zhao GuoPing, Hu JianPing, Wang JiRong, Zhang Ming. Experience in laparoscopic cholecystectomy in treatment of acute calculous cholecystitis: a clinical analysis of 86 cases[J]. Journal of Clinical Hepatology, 2018, 34(3): 517-520. doi: 10.3969/j.issn.1001-5256.2018.03.013
[4]	Xi GuangLi, Dong Hao. Clinical effect of laparoscopic cholecystectomy and prognostic analysis in patients with acute cholecystitis[J]. Journal of Clinical Hepatology, 2018, 34(2): 332-336. doi: 10.3969/j.issn.1001-5256.2018.02.022
[5]	Li ZhenLi, Yang Tian. Diagnosis and surgical treatment of xanthogranulomatous cholecystitis[J]. Journal of Clinical Hepatology, 2017, 33(2): 247-252. doi: 10.3969/j.issn.1001-5256.2017.02.007
[6]	Zhang JingZhe, Yu Kui. Integrated traditional Chinese and Western medicine therapy for acute and chronic cholecystitis[J]. Journal of Clinical Hepatology, 2017, 33(5): 838-842. doi: 10.3969/j.issn.1001-5256.2017.05.009
[7]	Zhao Bin, Qing XiaoSong, Lai Zhao. Clinical effect of laparoscopic versus open cholecystectomy in treatment of patients with portal hypertension complicated by gallstones[J]. Journal of Clinical Hepatology, 2017, 33(5): 888-891. doi: 10.3969/j.issn.1001-5256.2017.05.019
[8]	Tan ZhanHai, Zhu GuangHui, Chen JianRong, Zhou LianMing, Yang Zhi, Zhang JiFa, Zhang XueLi, Dan YuanZhou. Clinical effect of laparoscopic cholecystectomy combined with laparoscopic choledocholithotomy T-tube drainage in treatment of gallbladder and common bile duct stones[J]. Journal of Clinical Hepatology, 2017, 33(5): 883-887. doi: 10.3969/j.issn.1001-5256.2017.05.018
[9]	Zhao HongGuang, Liu Kai, Liu YaHui. The most appropriate timing for selective laparoscopic cholecystectomy after percutaneous transhepatic gallbladder drainage in patients with acute severe cholecystitis aged above 60 years[J]. Journal of Clinical Hepatology, 2017, 33(4): 705-710. doi: 10.3969/j.issn.1001-5256.2017.04.021
[10]	Yang YaLin, Xu ZhiJie. Postoperative infection in laparoscopic cholecystectomy in treatment of acute cholecystitis complicated by choleperitonitis[J]. Journal of Clinical Hepatology, 2017, 33(1): 98-101. doi: 10.3969/j.issn.1001-5256.2017.01.021
[11]	Chen LuBin, Lu: XiaoHui, Guo Xin. Diagnosis,treatment,and outcome of Mirizzi syndrome in the perioperative period of laparoscopic cholecystectomy[J]. Journal of Clinical Hepatology, 2016, 32(7): 1354-1356. doi: 10.3969/j.issn.1001-5256.2016.07.030
[12]	Ran JiangLin, Zhang ShaoMao, Wen Qiang. Effects of laparoscopic retrograde cholecystectomy versus partial cholecystectomy in treatment of complex bile duct diseases: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(4): 750-753. doi: 10.3969/j.issn.1001-5256.2016.04.030
[13]	Zhou JingSong, Pu DongLi, Du ZiYou. Clinical effects of laparoscopy and laparotomy in treatment of gangrenous cholecystitis[J]. Journal of Clinical Hepatology, 2016, 32(5): 914-917. doi: 10.3969/j.issn.1001-5256.2016.05.021
[14]	Fan Hua, Zhang ShengJun. Comparison of efficacy between choledochoscopic gallbladder-preserving cholelithotomy and laparoscopic cholecystectomy in treatment of gallstones: a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1665-1670. doi: 10.3969/j.issn.1001-5256.2015.10.026
[15]	Wang WeiHua. Clinical efficacy of percutaneous transhepatic cholecystostomy combined with laparoscopic cholecystectomy for elderly patients with severe calculous cholecystitis[J]. Journal of Clinical Hepatology, 2015, 31(8): 1291-1294. doi: 10.3969/j.issn.1001-5256.2015.08.026
[16]	Liu Chao, Zhang Lei. Clinical efficacy of transumbilical single-port laparoscopic cholecystectomy in treatment of acute cholecystitis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1678-1681. doi: 10.3969/j.issn.1001-5256.2015.10.029
[17]	Dai JunTao, Zhang Ping, Wang Qing, Shen BoMing. Laparoscopic cholecystectomy for acute cholecystitis: clinical analysis of 216 cases[J]. Journal of Clinical Hepatology, 2014, 30(7): 647-649. doi: 10.3969/j.issn.1001-5256.2014.07.018
[18]	Xu DaHua. Evolution and current challenges of laparoscopic cholecystectomy[J]. Journal of Clinical Hepatology, 2013, 29(3): 166-168.
[19]	Yi ZhengHui, Wang DaQing, Chang YingBin. Surgical experience of laparoscopic cholecystectomy in 53 cases of acute cholecystitis [J]. Journal of Clinical Hepatology, 2013, 29(3): 194-195.
[20]	Xi RuGuang, Zhang ShaoGuang, Yang WanHong, Ding YanZhen. The application of intraoperative cholangiography in laparoscopic cholecystectomy[J]. Journal of Clinical Hepatology, 2011, 27(3): 300-301.

Supplements(0)

Cited By

Cited by

Periodical cited type(31)

1.	丁辉，苏雪梅，张蓉. 子宫内膜异位症患者血清GP73和SMAD2表达水平及临床价值研究. 现代检验医学杂志. 2025(01): 122-126+131 .
2.	王慧敏，谭炳芹，王万鹏，吴梦雪. 慢性乙型肝炎病毒感染相关肝病患者血清高尔基体蛋白73水平变化分析. 山东医药. 2025(01): 100-103+108 .
3.	张璨，张欢欢，高飞，任佩佩，罗明阳，闫冬，王馨，王莹莹，曾艳丽. 血清高尔基体蛋白73联合肝脏硬度评估慢性乙型肝炎病毒感染患者肝纤维化进展的价值. 中华实用诊断与治疗杂志. 2024(10): 1013-1018 .
4.	李述美，刘冰，刘仁伟，杨洁. GP73、IL-2R、miR-21预测慢性乙肝患者显著肝纤维化的临床价值. 重庆医学. 2024(23): 3575-3580 .
5.	安薪宇，乔杰，胡灵溪，王荣琦，南月敏. GP73对慢性肝病患者肝纤维化诊断价值的研究. 中华内科杂志. 2023(01): 49-53 .
6.	张航，刘近春. 血清高尔基体蛋白73在非酒精性脂肪性肝病中的作用. 临床肝胆病杂志. 2023(03): 657-662 . 本站查看
7.	马杨青，范海纳，孙鑫，刘成海. 高尔基体蛋白73(GP73)对慢性肝病的诊断价值. 临床肝胆病杂志. 2023(08): 1999-2004 . 本站查看
8.	张欢，雷学忠. 新型血清标志物高尔基体蛋白73在慢性乙型肝炎临床诊治中的研究进展. 华西医学. 2023(08): 1243-1246 .
9.	陈腾千，姜丽华，张生君，蒋义贵，罗佳，胡永敏，尤丽财. 高尔基体蛋白73在非酒精性脂肪性肝病中的应用价值. 黑龙江医学. 2023(17): 2053-2055+2059 .
10.	李雨蓉，姚明解，王杰. 序贯无创检测提高肝纤维化筛查效率. 肝脏. 2023(10): 1146-1149 .
11.	刘燕娜，姚明解，郑素军，陈香梅，刘向祎，胡鹏，欧启水，窦晓光，陈红松，段钟平，侯金林，南月敏，高志良，徐小元，庄辉，鲁凤民. 血清高尔基体蛋白73在慢性肝病患者中的临床应用. 中华肝脏病杂志. 2022(01): 4-8 .
12.	裴倩云，孙颖. 血清免疫球蛋白检验在肝衰竭患者的诊断价值. 系统医学. 2022(15): 103-105+118 .
13.	王鹏飞，刘树红，钱相君，翟相威，文夏杰，姚明解，赵景民，鲁凤民. 血清高尔基体蛋白73对丙型肝炎肝硬化的诊断价值研究. 中华肝脏病杂志. 2022(08): 879-884 .
14.	郑伟明，罗翠转，卢金英，骆晓豪，刘浩，梁栋伟. 血过氧化物酶增殖体激活受体γ与慢性乙型肝炎患者炎症的相关性. 中国肝脏病杂志(电子版). 2022(04): 42-47 .
15.	庄云英，张海燕，曾清芳. 慢性乙型肝炎肝纤维化的无创诊断研究进展. 肝脏. 2021(01): 84-87 .
16.	刘燕娜，姚明解，鲁凤民. 慢性肝病患者中血清高尔基体蛋白73的临床应用. 肝脏. 2021(02): 103-106 .
17.	Application of serum Golgi protein-73 in the management of chronic liver disease. 中华医学杂志英文版. 2021(07): 777-779 .
18.	罗双艳，何颖. 慢性乙肝患者肝脏炎症及纤维化的影响因素及其与血清高尔基体蛋白73的相关性. 医学信息. 2021(15): 5-8 .
19.	高伟，高虹，尹春梅，杨森林，范晓红，刘春亮，李雪卿，贾妮娜. 血清GP73与p62测定对HBV相关慢加急性肝衰竭患者短期预后的预测价值比较. 中华肝脏病杂志. 2021(09): 855-860 .
20.	王一奇，苑喜微，李冬冬，汤玉会，薛宁宁，崔璐瑶，刘领弟，南月敏. 血浆高尔基体蛋白73及相关模型诊断非酒精性脂肪性肝病的研究. 中华肝脏病杂志. 2021(12): 1170-1176 .
21.	张春林. 患儿脓毒症继发肝损伤的危险因素及血清高尔基体跨膜糖蛋白73、微小RNA-122a水平变化. 中国临床医生杂志. 2020(02): 236-238 .
22.	刘沁雨，常越，张青，丁玉平，李海. 高尔基体蛋白73对抗病毒治疗慢性乙型肝炎患者代偿期肝硬化的诊断价值. 解放军医药杂志. 2020(03): 86-91 .
23.	翟相威，刘树红，姚明解，钱相君，文夏杰，许强，赵景民，鲁凤民. 基于血清高尔基体蛋白73的代偿期乙型肝炎肝硬化无创诊断模型的建立及初步应用. 中华肝脏病杂志. 2020(01): 47-52 .
24.	范旭，单珊，刘立伟，贾继东. 血清高尔基糖蛋白73优于APRI、FIB-4对慢性HBV感染患者显著纤维化的诊断. 现代消化及介入诊疗. 2020(04): 529-532 .
25.	范旭，单珊，刘立伟，贾继东. 血清高尔基体跨膜糖73蛋白及其他生物标志物联合检测在AFP阴性小肝癌诊断中的意义. 现代消化及介入诊疗. 2020(04): 435-439+443 .
26.	刘沁雨，常越，张文，张青，卢诚震，李海. GP73预测慢性乙型肝炎患者肝硬化进展研究. 武警医学. 2020(04): 317-323 .
27.	马玲玉，甄一宁，罗云萍，段昭君. gp73在小鼠肝纤维化肝组织中的表达及机制. 基础医学与临床. 2020(06): 771-776 .
28.	刘沁雨，常越，张青，丁玉平，李海. 血清GP73与PYGO2对已长期抗病毒治疗慢性乙型肝炎肝硬化的诊断价值. 山东医药. 2020(29): 64-66 .
29.	李佳娜，郑瑞琦，李娜，胡玉琳. 高尔基体蛋白73的生物学特征及在肝纤维化和肝硬化中的诊断价值. 临床肝胆病杂志. 2019(06): 1361-1364 . 本站查看
30.	王春艳，纪冬，马丽君，陈松海，王晶晶，邵清，陈国凤，韩萍. 慢性乙型肝炎患者血清高尔基体蛋白73及其与肝脏炎症及纤维化的相关性. 解放军医学杂志. 2019(06): 503-507 .
31.	宋莹，李世朋，焦伟伟. 血清HMGB1、TGFβ1及GP73检测对脓毒症并发肝损伤预后的评估价值. 分子诊断与治疗杂志. 2019(06): 457-461 .

Other cited types(12)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1421) PDF downloads(191)

Blocking and reversing liver fibrosis with traditional Chinese medicine compound prescriptions: Beyond the known frontiers

DOI: 10.3969/j.issn.1001-5256.2023.02.004